Cargando…

Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients

BACKGROUND: The occurrence of Chemotherapy-induced neutropenia (CIN) was reported to be a predictor of better survival in several cancers. The objective of our study is to evaluate the relationship between the timing of CIN and prognosis. METHODS: Between June 2012 and August 2014, 290 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yang, Wang, YanRong, Shi, Yan, Dai, GuangHai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379656/ https://www.ncbi.nlm.nih.gov/pubmed/28376763 http://dx.doi.org/10.1186/s12885-017-3240-6

Ejemplares similares

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer
por: Aoshima, Hiroyuki, et al.
Publicado: (2022)

Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
por: Lu, C-Y, et al.
Publicado: (2013)

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma
por: Cai, Zhiyuan, et al.
Publicado: (2021)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
por: Zhao, Shen, et al.
Publicado: (2022)

The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer
por: Areepium, Nutthada, et al.
Publicado: (2023)

Conversion to resectability using transcatheter arterial chemoembolization alternating with mFOLFOX6 in patients with colorectal liver metastases
por: Wang, Shuai, et al.
Publicado: (2019)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
por: Wang, Feng, et al.
Publicado: (2019)

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients
por: Sugimoto, Shinichi, et al.
Publicado: (2009)

Timing of chemotherapy‐induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first‐line chemotherapy with oxaliplatin and capecitabine: a retrospective study
por: Wang, Yanrong, et al.
Publicado: (2018)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
por: Naiki, Taku, et al.
Publicado: (2017)

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
por: Horimatsu, Takahiro, et al.
Publicado: (2017)

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases
por: Suetsugu, Tomonari, et al.
Publicado: (2018)

Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study
por: Wang, Tianxiao, et al.
Publicado: (2022)

Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study
por: He, Min-Ke, et al.
Publicado: (2017)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma
por: Chen, Yang, et al.
Publicado: (2017)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report
por: Fan, Xiumei, et al.
Publicado: (2023)

Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients
por: KUMAMOTO, KENSUKE, et al.
Publicado: (2013)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
por: Hecht, J Randolph, et al.
Publicado: (2015)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

A Rare Case of Severe Lactic Acidosis from 5-Fluorouracil after mFOLFOX6 Treatment in a Patient with Advanced Gastric Cancer
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpikcqmrhj4pj4i0nqscin03fk